Galectin Therapeutics Inc (GALT): Total Assets
$19.53M
As of 2025-12-31
$14.83M
As of 2026-06-30
-2.8%
3-year compound annual growth
-8.0%
5-year compound annual growth
-3.0%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $19.53M | +11.6% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $17.50M | -38.0% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $28.20M | +32.5% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $21.29M | -49.1% | 2024-03-29, Balance as of period end |
| 2021-12-31 | $41.83M | +41.3% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $29.60M | -38.9% | 2022-03-31, Balance as of period end |
| 2019-12-31 | $48.47M | +438.2% | 2021-03-31, Balance as of period end |
| 2018-12-31 | $9.01M | +116.4% | 2020-03-16, Balance as of period end |
| 2017-12-31 | $4.16M | -73.7% | 2019-03-06, Balance as of period end |
| 2016-12-31 | $15.79M | -40.2% | 2018-03-29, Balance as of period end |
| 2015-12-31 | $26.41M | -11.0% | 2017-03-28, Balance as of period end |
| 2014-12-31 | $29.68M | +177.0% | 2016-03-15, Balance as of period end |
| 2013-12-31 | $10.71M | +12.0% | 2015-03-18, Balance as of period end |
| 2012-12-31 | $9.56M | +44.6% | 2014-03-21, Balance as of period end |
| 2011-12-31 | $6.61M | +5.0% | 2013-03-29, Balance as of period end |
| 2010-12-31 | $6.30M | n/a | 2012-03-30, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Galectin Therapeutics Inc (GALT) | 2025-12-31 | $19.53M | +11.6% |
| Lftd Partners Inc. (LIFD) | 2025-12-31 | $19.27M | -59.5% |
| Marker Therapeutics, Inc. (MRKR) | 2025-12-31 | $19.07M | -13.4% |
| Genelux Corp (GNLX) | 2025-12-31 | $19.03M | -45.2% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $20.27M | -14.8% |
| Quoin Pharmaceuticals Ltd. (QNRX) | 2025-12-31 | $20.39M | +29.8% |
| Nexentis Technologies Inc. (NXTS) | 2025-12-31 | $20.41M | +273.4% |
| Galmed Pharmaceuticals Ltd. (EOCN) | 2025-12-31 | $18.63M | +0.7% |
| Jyong Biotech Ltd. (MENS) | 2025-12-31 | $20.78M | +226.4% |
Compare GALT, LIFD, MRKR, GNLX side by side · Screen every company in Pharmaceutical Preparations ↗